Holen Sie sich die Stockscreener-App
65.13
3.50%
-2.7741
Schlusskurs vom Vortag:
$67.90
Offen:
$67.87
24-Stunden-Volumen:
549.16K
Relative Volume:
0.87
Marktkapitalisierung:
$3.36B
Einnahmen:
$379.25M
Nettoeinkommen (Verlust:
$-77.34M
KGV:
-40.40
EPS:
-1.6122
Netto-Cashflow:
$-27.87M
1W Leistung:
-6.23%
1M Leistung:
-3.79%
6M Leistung:
+39.27%
1J Leistung:
+51.29%
1-Tages-Spanne:
$65.10
$69.46
1-Wochen-Bereich:
$63.48
$71.98
52-Wochen-Spanne:
$36.88
$78.54
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Vergleichen Sie MIRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
65.36 | 3.49B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.06 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.57 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.91 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.93 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald - Yahoo Finance
Mirum to buy Bluejay for up to $820m in rare liver disease push - Yahoo Finance
Mirum Pharmaceuticals stock rises as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com UK
Morgan Stanley Raises Price Target on Mirum Pharmaceuticals to $95 From $81, Keeps Overweight Rating - marketscreener.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Jump Financial LLC - MarketBeat
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - BioSpace
Five things for pharma marketers to know for Tuesday, December 9, 2025 - Medical Marketing and Media
Baird raises Mirum Pharmaceuticals stock price target to $88 on Bluejay acquisition - Investing.com Canada
Mirum Pharma to buy Bluejay Therapeutics for up to $820 million - WTVB
Mirum Adds To Rare Liver Disease Portfolio With Bluejay Acquisition - Citeline News & Insights
Mirum Pharmaceuticals stock rises as Morgan Stanley reiterates Overweight rating - Investing.com Canada
Mirum Pharmaceuticals, Inc. (MIRM) Bluejay Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:MIRM) 2025-12-08 - Seeking Alpha
MIRM: Acquisition brings a breakthrough hepatitis delta therapy, expanding rare disease leadership - TradingView
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay - BioPharma Dive
Mirum Pharmaceuticals, Inc. entered into a definitive agreement to acquire Bluejay Therapeutics, Inc for $820 million. - marketscreener.com
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' - MSN
Latham & Watkins Advises Bluejay Therapeutics in US$620 Million+ Acquisition by Mirum Pharmaceuticals - Latham & Watkins LLP
Mirum expands into liver diseases with Bluejay Therapeutics acquisition - Seeking Alpha
Mirum Pharma to buy Bluejay Therapeutics for up to $820M - Axios
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Gl - pharmiweb.com
Mirum Pharmaceuticals To Acquire Bluejay Therapeutics In Rare Liver Disease Expansion - Nasdaq
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug - marketscreener.com
Mirum Pharmaceuticals to Acquire Bluejay Therapeutics - Contract Pharma
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics - marketscreener.com
Mirum Pharmaceuticals to acquire HBM portfolio company Bluejay Therapeutics for up to USD 820 million - TradingView
Mirum to acquire Bluejay for $620 million, adding HDV treatment - Investing.com
Mirum Pharmaceuticals enters into definitive agreement to acquire Bluejay Therapeutics - marketscreener.com
Mirum to acquire Bluejay for $620 million, adding HDV treatment By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals (NASDAQ: MIRM) to acquire Bluejay Therapeutics, adds HDV drug brelovitug and $200M PIPE - Stock Titan
Mirum Pharmaceuticals (MIRM) up 1.3% since last earnings report: Can it continue? - MSN
Affinity Asset Advisors LLC Cuts Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
MIRM SEC FilingsMirum Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
How geopolitical risks impact Mirum Pharmaceuticals Inc. (08D) stockWeekly Earnings Recap & AI Driven Stock Price Forecasts - Newser
How Mirum Pharmaceuticals Inc. (08D) stock responds to job market shiftsJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
Is Mirum Pharmaceuticals Inc. (08D) stock worth buying before Fed action2025 Market Sentiment & Daily Market Momentum Tracking - Newser
Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? - Yahoo Finance
JPMorgan Chase & Co. Purchases 192,340 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals, Inc. $MIRM Position Boosted by Russell Investments Group Ltd. - MarketBeat
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 - Yahoo Finance
Will Mirum Pharmaceuticals Inc. stock continue upward momentumWeekly Trade Report & Verified Stock Trade Ideas - Newser
Mirum Pharmaceuticals Insider Sold Shares Worth $3,700,000, According to a Recent SEC Filing - marketscreener.com
Mirum Pharmaceuticals Director Sells 50,000 Shares - TradingView
Mirum Pharmaceuticals(MIRM.US) Director Sells US$3.7 Million in Common Stock - 富途牛牛
Mirum Pharmaceuticals (MIRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study - sharewise.com
Will Mirum Pharmaceuticals Inc. (08D) stock gain from green policiesEarnings Performance Report & Precise Swing Trade Entry Alerts - Newser
Mirum enrolls first patient in Fragile X syndrome oral therapy study - Investing.com Canada
Mirum enrolls first patient in Fragile X syndrome oral therapy study By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals advances BLOOM Phase 2 study for Fragile X therapy - Traders Union
Mirum Pharmaceuticals Says First Patient Enrolled in Phase 2 Fragile X Syndrome Therapy Trial of MRM-3379 - MarketScreener
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):